Modulation of immunity in cancer patients by prostaglandin antagonists.
Braun
D P
DP
Department of Internal Medicine, Rush Medical College, Chicago, Illinois 60612.
Taylor
S G
SG
Harris
J E
JE
D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000628:therapy*; D004341:Drug Evaluation; D006258:Head and Neck Neoplasms / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D007376:Interleukin-2 / Q000096:biosynthesis; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000628:therapy*; D010894:Piroxicam / Q000627:therapeutic use*; D011453:Prostaglandins / Q000378:metabolism
D007376:Interleukin-2; D011453:Prostaglandins; D010894:Piroxicam